Skip to main content

Zepatier Disease Interactions

There are 4 disease interactions with Zepatier (elbasvir / grazoprevir).

Major

Direct acting antivirals (applies to Zepatier) immunosuppression

Major Potential Hazard, Moderate plausibility. Applicable conditions: Immunodeficiency, Infectious Hepatitis

HBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive). HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients. All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy. Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.

References

  1. "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
  2. "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences (2014):
  3. "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC (2022):
  4. "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):
  5. "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences (2016):
  6. "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences (2017):
  7. "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical (2017):
View all 7 references
Major

Elbasvir (applies to Zepatier) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of elbasvir (which is available in combination with grazoprevir) is contraindicated in patients with moderate or severe hepatic impairment, or those with any history of hepatic decompensation.

References

  1. "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):
Major

Elbasvir (applies to Zepatier) liver transplant

Major Potential Hazard, Moderate plausibility. Applicable conditions: Organ Transplant

The safety and efficacy of elbasvir (available in combination with grazoprevir), have not been established in patients awaiting liver transplant or in liver transplant recipients.

References

  1. "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):
Major

Grazoprevir (applies to Zepatier) hepatic impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of is grazoprevir is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) due to the expected significantly increased in plasma concentration and the increased risk of alanine aminotransferase (ALT) elevations.

References

  1. "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):

Zepatier drug interactions

There are 225 drug interactions with Zepatier (elbasvir / grazoprevir).

Zepatier alcohol/food interactions

There is 1 alcohol/food interaction with Zepatier (elbasvir / grazoprevir).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.